|
CN108685923A
|
|
Application of the Wnt signal path inhibitor in treating LGR5 positive cancers
|
|
CN107510652A
|
|
Liposomal formulation for delivering Wnt signal path inhibitor and preparation method thereof
|
|
CN107441045A
|
|
Liposomal formulation for delivering Wnt signal path inhibitor and preparation method thereof
|
|
JP2017095498A
|
|
Wnt SIGNALING INHIBITOR, COMPOSITION, AND COMPOUND AS USE THEREFOR
|
|
AU2014244506A1
|
|
Compounds for treatment of fibrosis diseases
|
|
CA2905830A1
|
|
Quinazoline and naphthyridine derivatives useful in the treatment of cancer
|
|
CN106188045A
|
|
Compound, compositions and application thereof as WNT signal transduction inhibitor
|
|
WO2013159349A1
|
|
Method for producing cardiomyocytes
|
|
CN103443098A
|
|
Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
|
|
CN102558173A
|
|
Compound inhibiting conduction of WNT signal, and composition and application thereof
|
|
WO2012088712A1
|
|
Compound as wnt signaling inhibitor, composition, and use thereof
|
|
CN104530042A
|
|
Compound inhibiting WNT signal conduction, composition, and application of two
|
